PMID- 38462363
OWN - NLM
STAT- MEDLINE
DCOM- 20240312
LR  - 20240312
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 104
IP  - 11
DP  - 2024 Mar 19
TI  - [Analysis of transfusion effect of different platelet matching schemes in 
      patients with platelet transfusion refractoriness].
PG  - 865-869
LID - 10.3760/cma.j.cn112137-20231204-01281 [doi]
AB  - Objective: To analyze the transfusion effect of different platelet matching 
      schemes in patients with platelet transfusion refractoriness (PTR). Methods: A 
      total of 94 patients with PTR received by Taiyuan Blood Center from January to 
      December 2021 were retrospectively analyzed, including 26 males and 68 females, 
      aged 53(34,66) years. Platelet antibody screening was performed by enzyme-linked 
      immunosorbent assay (ELISA). For patients with positive human leukocyte antigen 
      (HLA) class Ⅰ antibodies, Luminex platform liquid chip assay was used to identify 
      the specificity of antibodies, and platelets with missing allelic expression 
      antigen corresponding to their specific antibodies were found in the platelet 
      donor gene database established in our laboratory. For patients with negative 
      class HLA-Ⅰ antibody screening, medium and high-resolution HLA-A and B alleles 
      were genotyped by polymerase chain reaction restriction sequence specific 
      oligonucleotide (PCR-SSO), and the compatible platelets were searched from the 
      platelet donor gene database by HLA cross-reactive group genotype matching scheme 
      or directly selected by serological cross-matching. The PCI compliance rate and 
      total transfusion effective rate of different mismatch site groups and different 
      matching scheme groups were statistically analyzed. Results: Platelet antibody 
      was detected in 39 of 94 PTR patients with a positive rate of 41.5%, and all of 
      them were HLA-Ⅰ antibodies, and 1 case was accompanied by human platelet antigen 
      (HPA) antibody. A total of 134 times of compatible platelets were supplied to 39 
      patients with HLA-Ⅰ antibody positive by using antibody avoidance matching 
      method. And the total effective rate of transfusion was 97.8% (131/134); The PCI 
      compliance rates of HLA-A antigen mismatch, HLA-B antigen mismatch and HLA-A and 
      B antigen mismatch groups were 81.6% (31/38), 86.5% (32/37) and 78.6% (22/28), 
      respectively. The total effective rate of transfusion was 97.4% (37/38), 94.6% 
      (35/37) and 100% (28/28), respectively, with no statistical significance (all 
      P>0.05). A total of 118 times of compatible platelets were provided by HLA 
      antigen cross-reaction group genotype matching and serological cross-matching, 90 
      transfusion effects were collected during follow-up, and the total effective rate 
      was 76.7% (69/90). Conclusion: The combination of different platelet matching 
      schemes can improve the PCI compliance rate and the total effective rate of 
      transfusion in PTR patients.
FAU - Liang, Y J
AU  - Liang YJ
AD  - Laboratory of Blood Transfusion Technology, Taiyuan Blood Center, Taiyuan 030024, 
      China.
FAU - Wang, H
AU  - Wang H
AD  - Laboratory of Blood Transfusion Technology, Taiyuan Blood Center, Taiyuan 030024, 
      China.
FAU - Zhao, P Z
AU  - Zhao PZ
AD  - Laboratory of Blood Transfusion Technology, Taiyuan Blood Center, Taiyuan 030024, 
      China.
FAU - Wang, F
AU  - Wang F
AD  - Laboratory of Blood Transfusion Technology, Taiyuan Blood Center, Taiyuan 030024, 
      China.
FAU - Li, Q
AU  - Li Q
AD  - Laboratory of Blood Transfusion Technology, Taiyuan Blood Center, Taiyuan 030024, 
      China.
FAU - Xu, Y
AU  - Xu Y
AD  - Laboratory of Blood Transfusion Technology, Taiyuan Blood Center, Taiyuan 030024, 
      China.
FAU - Wu, Y X
AU  - Wu YX
AD  - Laboratory of Blood Transfusion Technology, Taiyuan Blood Center, Taiyuan 030024, 
      China.
FAU - Zhang, D M
AU  - Zhang DM
AD  - Laboratory of Blood Transfusion Technology, Taiyuan Blood Center, Taiyuan 030024, 
      China.
FAU - He, X H
AU  - He XH
AD  - Department of Blood Transfusion, Shanxi Bethune Hospital, Taiyuan 030000, China.
LA  - chi
GR  - 2021XM13/Key Medical Research Project of Shanxi Province/
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-A Antigens)
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Platelet Transfusion
MH  - *Percutaneous Coronary Intervention
MH  - Retrospective Studies
MH  - Blood Platelets
MH  - *Thrombocytopenia
MH  - Antibodies
MH  - HLA Antigens
MH  - HLA-A Antigens
EDAT- 2024/03/11 00:42
MHDA- 2024/03/12 06:42
CRDT- 2024/03/10 22:18
PHST- 2024/03/12 06:42 [medline]
PHST- 2024/03/11 00:42 [pubmed]
PHST- 2024/03/10 22:18 [entrez]
AID - 10.3760/cma.j.cn112137-20231204-01281 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2024 Mar 19;104(11):865-869. doi: 
      10.3760/cma.j.cn112137-20231204-01281.